To test whether PHGDH inhibitor could work synergistically with Sorafenib in suppressing HCC growth, we treated MHCC97L cells with 4 μM Sorafenib alone, 40 μM NCT-503 alone, and 4 μM Sorafenib, and 40 μM NCT-503 together for 48 h. This evidence concerns the gene PHGDH and hepatocellular carcinoma.